ORYZON to Provide Corporate Progress Updates at Several Events in May
May 09, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
Spectral AI Announces 2024 First Quarter Financial Results
May 07, 2024 16:15 ET
|
Spectral AI, Inc.
Q1 Overview Research & Development Revenue of $6.3 MillionImproved Capital Structure Reflected in Cash of $10.2 MillionDeepView AI®-Burn Devices Deployed in UK; Expect Commercial Revenue in 2H...
Cogent Biosciences Reports First Quarter 2024 Financial Results
May 07, 2024 08:00 ET
|
Cogent Biosciences, Inc.
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient...
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer
May 07, 2024 07:00 ET
|
CMR Surgical
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer Shlomi Cohen is a medical devices expert with significant financial and operational experience. CAMBRIDGE, UK – 7 May 2024, 07:00...
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer
May 07, 2024 02:00 ET
|
CMR Surgical
CMR Surgical appoints Shlomi Cohen as Chief Financial Officer Shlomi Cohen is a medical devices expert with significant financial and operational experience. CAMBRIDGE, UK – 7 May 2024, 07:00...
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 07, 2024 01:00 ET
|
VALNEVA
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on...
HEALWELL AI Inc. Announces Upsize of Bought Deal to Up to $20 Million
May 06, 2024 15:17 ET
|
HEALWELL AI Inc.
HEALWELL AI INC. ANNOUNCES UPSIZE OF BOUGHT DEAL TO UP TO $20 MILLION
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
May 06, 2024 12:03 ET
|
Oryzon Genomics, S.A.
Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans...
HEALWELL AI Announces $16 Million Bought Deal Private Placement
May 06, 2024 08:00 ET
|
HEALWELL AI Inc.
HEALWELL AI ANNOUNCES $16 MILLION BOUGHT DEAL PRIVATE PLACEMENT
ImPact Biotech Presents Preliminary Phase 3 Results from ENLIGHTED Study of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer
May 06, 2024 08:00 ET
|
ImPact Biotech
Encouraging response rate shown; CR in 67% (6/9) of patients who completed the Induction Treatment Phase Padeliporfin VTP generally well-tolerated, consistent with prior results and reinforcing...